–
(CercleFinance.com) – AB Science reported last night a case of ‘complete response’ in one of the patients treated as part of its phase I/II study in acute mylodic leukemia (AML). first cycle of treatment, ie after three consecutive days of treatment with its product AB8939, the company claims to have observed a ‘drastic’ reduction in leukemia cells.
The term ‘complete response’ applies when all signs of the disease have disappeared after treatment has been instituted. Remarkably, according to AB Science, this response was obtained at a very low dose of AB8939, and the patient also showed excellent tolerance, with no treatment-related toxicity. signifies that a third cycle has been initiated.
For Professor Olivier Hermine, chairman of the scientific committee of AB Science and member of the Academy of Sciences, said, these preliminary clinical data “provide the most encouraging signs to date that AB8939 could be well suited for the treatment of high-risk recurrent/refractory AML. AML is a serious, life-threatening disease and the most common cause of death among leukemias, largely because patients develop drug resistance to existing first-line drugs .
Listed on the Paris Bourse, the AB Science share rose 5.2% after this announcement. Copyright (c) 2023 CercleFinance.com. All rights reserved.
